Drug intelligence / Profile preview

Orthovisc mini

Development stage: Unknown
Lead developer: Anika Therapeutics
Administration: Intraarticular

Overview

Orthovisc mini is an ultra-pure, high molecular weight injectable hyaluronic acid (HA) viscosupplement developed by Anika Therapeutics. It consists of sodium hyaluronate (15 mg/mL) dissolved in physiological saline and is supplied in a 1.0 mL sterile glass syringe. The product is designed to provide lubrication and mechanical support to smaller synovial joints, such as the thumb, toe, hand, wrist, and ankle, to alleviate osteoarthritis pain. It acts as a viscoelastic supplement or replacement for synovial fluid in the joint space. While available in the European Economic Area and other international markets, it is not currently approved for use in the United States.

Brand names: Orthovisc mini
Other names: sodium hyaluronate

Beyond the preview

Go deeper on Orthovisc mini.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orthovisc mini.

Explore the full profile